There are currently 66 clinical trials in Arlington, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Clinical Research Institute, GSK Investigational Site, Texas Retina Associates and Texas Clinical Research Institute, Llc. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251
Recruiting
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
Gender:
All
Ages:
50 years and above
Trial Updated:
04/14/2024
Locations: Texas Retina Associates, Arlington, Texas
Conditions: Neovascular Age-Related Macular Degeneration
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: The Center for Cancer & Blood Disorders - Magnolia,515 W. Mayfield Rd., Arlington, Texas
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT05620836
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Investigative Site US235, Arlington, Texas
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540
Recruiting
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine togethe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Arlington Family Res. Ctr Inc, Arlington, Texas
Conditions: Type 2 Diabetes Mellitus
Register for Updates
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544
Recruiting
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Arlington Center for Dermatology, Arlington, Texas
Conditions: Plaque Psoriasis
Register for Updates
Effects of Exercise and Virtual Reality on Depression
NCT05973461
Recruiting
This study is evaluating the effects of riding on a cycle ergometer while experiencing virtual reality to determine its effect on mood.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/08/2024
Locations: UTArlington, Arlington, Texas
Conditions: Symptoms of Depression
Register for Updates
RESTORE: An RCT to Evaluate the Efficacy of the Revi System
NCT06217328
Recruiting
The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.
Gender:
All
Ages:
21 years and above
Trial Updated:
04/07/2024
Locations: Urology Partners of North Texas, Arlington, Texas
Conditions: Urinary Urge Incontinence
Register for Updates
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
NCT05685433
Recruiting
A prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the eCoin® implanted tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/06/2024
Locations: UPNT Research Institute, Arlington, Texas
Conditions: Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Register for Updates
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237
Recruiting
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Arlington Cancer Center, Arlington, Texas
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis
NCT05070858
Recruiting
The primary objective is: To evaluate the effect of pozelimab + cemdisiran on daily functioning that is impacted by signs and symptoms in patients with symptomatic generalized myasthenia gravis (gMG) The secondary objectives of the study are: To evaluate the effect of pozelimab + cemdisiran (ie, combination) and cemdisiran monotherapy on: Clinician-assessed signs of myasthenia gravis (MG) and muscle strength Daily functioning that is impacted by signs and symptoms in patients with symptomati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Texas Institute for Neurological Disorders - Arlington, Arlington, Texas
Conditions: Generalized Myasthenia Gravis
Register for Updates
Black Women's Life Experience On Cardiovascular Health Via Ongoing Monitoring
NCT06150989
Recruiting
This pilot study uses a state-of-the-science combination of remote behavioral monitoring, real-time experience sampling, in-lab physiological assessments, and extraction of neighborhood-level characteristics to (1) Examine the impact of daily experience (i.e., racial discrimination, affective states, stress) on health behaviors (i.e., physical activity, sedentary behavior, sleep) at the intrapersonal level among Black women; (2) Test the association between daily behaviors and impairments in bio... Read More
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
04/03/2024
Locations: The University of Texas at Arlington, Arlington, Texas
Conditions: Cardiovascular Diseases, Heart Disease Risk Factors
Register for Updates
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
NCT05832931
Recruiting
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2024
Locations: Site Number: USA037-1, Arlington, Texas
Conditions: Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Register for Updates